VANI Overview

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.

Wall Street analysts forecast VANI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VANI is4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Vivani Medical Inc revenue for the last quarter amounts to 0.00 USD, decreased

Vivani Medical Inc. EPS for the last quarter amounts to -0.09 USD, decreased -18.18

Vivani Medical Inc (VANI) has 42 emplpoyees as of March 31 2026.

Today VANI has the market capitalization of 79.40M USD.